Corebridge Financial’s Regulus Therapeutics RGLS Stock Holding History

Corebridge Financial’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,938	Closed	-$54.1K	–	2189
2025 Q1	$54.1K	Sell	30,938 -459	-1%	-$606	﹤0.01%	2708
2024 Q4	$49.6K	Sell	31,397 -2,370	-7%	-$3.64K	﹤0.01%	2830
2024 Q3	$53K	Sell	33,767 -207	-0.6%	-$342	﹤0.01%	2856
2024 Q2	$61K	Buy	+33,974	New	+$78.8K	﹤0.01%	2836

Other funds holding RGLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Corebridge Financial's RGLS Position: Q2 2025 in Review

Corebridge Financial sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 30,938 shares — an estimated $54.1K sold.

Corebridge Financial first reported a position in RGLS in Q2 2024 and held it in 4 quarters. The position peaked at $61K in Q2 2024. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

Corebridge Financial reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
Corebridge Financial sold 30,938 Regulus Therapeutics shares in Q2 2025, an estimated $54.1K.
Corebridge Financial first reported a position in Regulus Therapeutics in Q2 2024 and held it in 4 quarters.
Corebridge Financial's Regulus Therapeutics position peaked at $61K in Q2 2024.
0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.